Jupiter Asset Management Ltd. Buys Shares of 523,908 Option Care Health, Inc. $OPCH

Jupiter Asset Management Ltd. purchased a new position in Option Care Health, Inc. (NASDAQ:OPCH) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 523,908 shares of the company’s stock, valued at approximately $14,544,000. Jupiter Asset Management Ltd. owned 0.33% of Option Care Health at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Compass Wealth Management LLC increased its stake in shares of Option Care Health by 25.6% in the 3rd quarter. Compass Wealth Management LLC now owns 232,053 shares of the company’s stock worth $6,442,000 after purchasing an additional 47,275 shares in the last quarter. Prospector Partners LLC bought a new stake in Option Care Health during the third quarter valued at about $4,176,000. GSA Capital Partners LLP increased its position in Option Care Health by 58.4% in the third quarter. GSA Capital Partners LLP now owns 40,531 shares of the company’s stock worth $1,125,000 after buying an additional 14,947 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Option Care Health by 29.1% in the third quarter. State of New Jersey Common Pension Fund D now owns 76,403 shares of the company’s stock worth $2,121,000 after buying an additional 17,237 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Option Care Health by 4.9% in the third quarter. HighTower Advisors LLC now owns 436,147 shares of the company’s stock worth $12,107,000 after buying an additional 20,302 shares during the period. Institutional investors own 98.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OPCH. Barrington Research boosted their price objective on Option Care Health from $38.00 to $42.00 and gave the company an “outperform” rating in a research note on Friday, January 16th. TD Cowen reiterated a “hold” rating on shares of Option Care Health in a research report on Tuesday, January 27th. Truist Financial set a $40.00 price objective on shares of Option Care Health in a research note on Tuesday, January 13th. Jefferies Financial Group restated a “buy” rating and set a $37.00 target price on shares of Option Care Health in a research note on Tuesday, January 13th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Option Care Health from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Option Care Health currently has an average rating of “Moderate Buy” and an average price target of $37.58.

Option Care Health Price Performance

OPCH stock opened at $35.69 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.05 and a current ratio of 1.56. The company’s fifty day moving average price is $33.92 and its 200-day moving average price is $30.38. Option Care Health, Inc. has a one year low of $24.24 and a one year high of $36.80. The company has a market capitalization of $5.67 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.